Emboldened by strong data for its oral IL-23 inhibitor icotrokinra in psoriasis, Johnson & Johnson has said it will see if it can outperform its big-selling injectable therapy Stelara in a ...

Specifically, the MHRA approved Zynyz as a first- and second-line treatment for adults with advanced squamous cell carcinoma ...

Asundexian has been approved by the FDA under the Sunharbo brand name for use in combination with antiplatelet therapy to ...

Hims & Hers is also offering compounded formulations of other unapproved peptides, including sermorelin, which some people ...

The approval gives Lilly first-mover advantage in China – the world's second-largest pharma market – and an edge over Novo, ...

Patients with muscle-invasive bladder cancer can now receive NHS treatment with a regimen of MSD's Keytruda and Astellas' ...

Earlier this year I was sent a certificate showing 99.6% purity. It had a lab name, a test date, and a clean chromatogram. It ...

UK-based startup Oyster Therapeutics has raised $60 million in first-round financing that will be used to advance its tau ...

Theramex, a London, UK-based specialty pharma company focusing on women's health, is changing hands in a deal reportedly ...

Amazon Web Services (AWS) has committed $100 million in AI and cloud technology capacity to support the building of health ...

The takeover deal – worth up to $1.15 billion including $550 million in upfront cash – will upgrade the Dutch biotech's ...

Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies Zepbound and Foundayo sold ...